Oncology · 1 h ago
Cohort Examines Lu-177 PSMA Survival by Taxane Sequencing in Prostate Cancer
A US electronic health record cohort study evaluated Lu-177 PSMA outcomes in 850 patients with metastatic prostate cancer after androgen receptor pathway inhibitor treatment. Median overall survival ranged from 12 to 16 months across taxane-sequencing groups, but the observational findings do not establish an optimal sequence.
- US cohort included 850 patients treated with Lu-177 PSMA.
- Median overall survival ranged from 12 to 16 months.
- Only 35 patients received taxane after Lu-177 PSMA.
- Observational findings do not establish an optimal treatment sequence.
A JAMA Network Open cohort study examined outcomes with lutetium Lu 177 vipivotide tetraxetan (Lu-177 PSMA) by treatment line and taxane sequencing. Researchers used electronic health records from US community and academic oncology practices to identify 850 patients treated after an androgen receptor pathway inhibitor between December 2018 and June 2025. Median age was 74 years, and 70.4% received community-based care. Primary endpoints were clinical time to next treatment, defined as next systemic therapy or death, and overall survival.
Among 466 patients who received taxane before Lu-177 PSMA, median time to next treatment was 8.0 months and median overall survival was 12.0 months (95% CI, 11.0–13.0). Corresponding estimates were 10.0 and 14.0 months (95% CI for survival, 13.0–17.0) among 349 patients who never received taxane. Among 35 patients receiving taxane after Lu-177 PSMA, estimates were 6.0 and 16.0 months (95% CI for survival, 13.0–not reached).
The authors described outcomes as broadly consistent across treatment lines and sequencing groups. These real-world estimates may support patient counseling, but nonrandomized comparisons and the small post–Lu-177 taxane group limit conclusions about sequencing. The supplied abstract provides no numerical treatment-line comparisons. Prospective studies are needed to determine the optimal strategy.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
JAMA Network Open: Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.